BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 34210801)

  • 1. UVB mutagenesis differs in
    Bowman RL; Hennessey RC; Weiss TJ; Tallman DA; Crawford ER; Murphy BM; Webb A; Zhang S; La Perle KM; Burd CJ; Levine RL; Shain AH; Burd CE
    Life Sci Alliance; 2021 Sep; 4(9):. PubMed ID: 34210801
    [No Abstract]   [Full Text] [Related]  

  • 2. Ultraviolet radiation accelerates BRAF-driven melanomagenesis by targeting TP53.
    Viros A; Sanchez-Laorden B; Pedersen M; Furney SJ; Rae J; Hogan K; Ejiama S; Girotti MR; Cook M; Dhomen N; Marais R
    Nature; 2014 Jul; 511(7510):478-482. PubMed ID: 24919155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRAF/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage.
    Mar VJ; Wong SQ; Li J; Scolyer RA; McLean C; Papenfuss AT; Tothill RW; Kakavand H; Mann GJ; Thompson JF; Behren A; Cebon JS; Wolfe R; Kelly JW; Dobrovic A; McArthur GA
    Clin Cancer Res; 2013 Sep; 19(17):4589-98. PubMed ID: 23833303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Number of nevi and early-life ambient UV exposure are associated with BRAF-mutant melanoma.
    Thomas NE; Edmiston SN; Alexander A; Millikan RC; Groben PA; Hao H; Tolbert D; Berwick M; Busam K; Begg CB; Mattingly D; Ollila DW; Tse CK; Hummer A; Lee-Taylor J; Conway K
    Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):991-7. PubMed ID: 17507627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ablation of epidermal RXRα in cooperation with activated CDK4 and oncogenic NRAS generates spontaneous and acute neonatal UVB induced malignant metastatic melanomas.
    Chagani S; Wang R; Carpenter EL; Löhr CV; Ganguli-Indra G; Indra AK
    BMC Cancer; 2017 Nov; 17(1):736. PubMed ID: 29121869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ppp6c haploinsufficiency accelerates UV-induced BRAF(V600E)-initiated melanomagenesis.
    Kanazawa K; Kishimoto K; Nomura M; Kurosawa K; Kato H; Inoue Y; Miura K; Fukui K; Yamashita Y; Sato I; Tsuji H; Watanabe T; Tanaka T; Yasuda J; Tanuma N; Shima H
    Cancer Sci; 2021 Jun; 112(6):2233-2244. PubMed ID: 33743547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.
    Thomas NE; Edmiston SN; Alexander A; Groben PA; Parrish E; Kricker A; Armstrong BK; Anton-Culver H; Gruber SB; From L; Busam KJ; Hao H; Orlow I; Kanetsky PA; Luo L; Reiner AS; Paine S; Frank JS; Bramson JI; Marrett LD; Gallagher RP; Zanetti R; Rosso S; Dwyer T; Cust AE; Ollila DW; Begg CB; Berwick M; Conway K;
    JAMA Oncol; 2015 Jun; 1(3):359-68. PubMed ID: 26146664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
    Lázár V
    Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization.
    Lázár V; Ecsedi S; Vízkeleti L; Rákosy Z; Boross G; Szappanos B; Bégány A; Emri G; Adány R; Balázs M
    Melanoma Res; 2012 Jun; 22(3):202-14. PubMed ID: 22456166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GAB2 amplifications refine molecular classification of melanoma.
    Chernoff KA; Bordone L; Horst B; Simon K; Twadell W; Lee K; Cohen JA; Wang S; Silvers DN; Brunner G; Celebi JT
    Clin Cancer Res; 2009 Jul; 15(13):4288-91. PubMed ID: 19509136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRAF and NRAS mutations in melanoma and melanocytic nevi.
    Poynter JN; Elder JT; Fullen DR; Nair RP; Soengas MS; Johnson TM; Redman B; Thomas NE; Gruber SB
    Melanoma Res; 2006 Aug; 16(4):267-73. PubMed ID: 16845322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct sets of genetic alterations in melanoma.
    Curtin JA; Fridlyand J; Kageshita T; Patel HN; Busam KJ; Kutzner H; Cho KH; Aiba S; Bröcker EB; LeBoit PE; Pinkel D; Bastian BC
    N Engl J Med; 2005 Nov; 353(20):2135-47. PubMed ID: 16291983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RAF proteins exert both specific and compensatory functions during tumour progression of NRAS-driven melanoma.
    Dorard C; Estrada C; Barbotin C; Larcher M; Garancher A; Leloup J; Beermann F; Baccarini M; Pouponnot C; Larue L; Eychène A; Druillennec S
    Nat Commun; 2017 May; 8():15262. PubMed ID: 28497782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unexpected UVR and non-UVR mutation burden in some acral and cutaneous melanomas.
    Rawson RV; Johansson PA; Hayward NK; Waddell N; Patch AM; Lo S; Pearson JV; Thompson JF; Mann GJ; Scolyer RA; Wilmott JS
    Lab Invest; 2017 Feb; 97(2):130-145. PubMed ID: 28067894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical, environmental and histological distribution of BRAF, NRAS and TERT promoter mutations among patients with cutaneous melanoma: a retrospective study of 563 patients.
    Manrique-Silva E; Rachakonda S; Millán-Esteban D; García-Casado Z; Requena C; Través V; Kumar R; Nagore E
    Br J Dermatol; 2021 Mar; 184(3):504-513. PubMed ID: 32506424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KIT Suppresses BRAF
    Neiswender JV; Kortum RL; Bourque C; Kasheta M; Zon LI; Morrison DK; Ceol CJ
    Cancer Res; 2017 Nov; 77(21):5820-5830. PubMed ID: 28947418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The genetic heterogeneity and mutational burden of engineered melanomas in zebrafish models.
    Yen J; White RM; Wedge DC; Van Loo P; de Ridder J; Capper A; Richardson J; Jones D; Raine K; Watson IR; Wu CJ; Cheng J; Martincorena I; Nik-Zainal S; Mudie L; Moreau Y; Marshall J; Ramakrishna M; Tarpey P; Shlien A; Whitmore I; Gamble S; Latimer C; Langdon E; Kaufman C; Dovey M; Taylor A; Menzies A; McLaren S; O'Meara S; Butler A; Teague J; Lister J; Chin L; Campbell P; Adams DJ; Zon LI; Patton EE; Stemple DL; Futreal PA
    Genome Biol; 2013; 14(10):R113. PubMed ID: 24148783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma.
    Yaman B; Akalin T; Kandiloğlu G
    Am J Dermatopathol; 2015 May; 37(5):389-97. PubMed ID: 25357015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Ultraviolet A-induced DNA damage: role in skin cancer].
    Beani JC
    Bull Acad Natl Med; 2014 Feb; 198(2):273-95. PubMed ID: 26263704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SF3B1, NRAS, KIT, and BRAF Mutation; CD117 and cMYC Expression; and Tumoral Pigmentation in Sinonasal Melanomas: An Analysis With Newly Found Molecular Alterations and Some Population-Based Molecular Differences.
    Wroblewska JP; Mull J; Wu CL; Fujimoto M; Ogawa T; Marszalek A; Hoang MP
    Am J Surg Pathol; 2019 Feb; 43(2):168-177. PubMed ID: 30273197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.